Chen Bihua bought BBOT

August 11, 2025 · Form 4 insider transaction

Chen Bihua bought 1,762,760 shares of BridgeBio Oncology Therapeutics, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
1,762,760
Price
N/A
Total value
N/A
InsiderChen Bihua
RoleDirector, 10% owner
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateAugust 11, 2025
Filing dateAugust 13, 2025
Shares owned after3,305,470
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the "Business Combination Agreement"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP ("Fund IV"), received as consideration therefor, shares of common stock of the Issuer.; Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

View the original Form 4 on SEC EDGAR